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Background. Human immunodeﬁciency virus (HIV) infection and the use of antiretroviral therapy (ART) may increase the risk
of type 2 diabetes mellitus (T2DM). However, data from regions with a high burden of HIV/AIDS are limited. We determined the
prevalence of T2DM at the time of presentation to a large HIV clinic in Nigeria, as well as the incidence of diabetes 12 months
following ART initiation.
Methods. Data from patients enrolled for ART from 2011 to 2013 was analyzed, including 2632 patients on enrollment and 2452
reevaluated after 12 months of ART commencement. The presence of diabetes, and demographic, clinical, and biochemical data were
retrieved from standardized databases. CD4+, HIV RNA load, and hepatitis C virus status were noted. Bivariate and logistic regres-
sions were used to identify risk factors for T2DM.
Results. Baseline T2DM prevalence was 2.3% (95% conﬁdence interval, 1.8% – 2.9%); age, but not body mass index (BMI), was a
risk factor for diabetes. After 12 months of ART, an additional 5.3% had developed T2DM. Newly developed diabetes was not as-
sociated with age, but was associated with BMI. There were no signiﬁcant associations between prevalent or incident diabetes and
CD4+, viral load, or type of ART.
Conclusions. Diabetes is not uncommon in HIV-infected individuals at the time of presentation to HIV services. Patients ini-
tiating ART have a high risk of developing diabetes in the ﬁrst year of ART. Excessive weight gain should be avoided, as incident
diabetes was associated with a BMI ≥25.0 kg/m2.
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Diabetes is a major public health concern worldwide and is rap-
idly increasing in sub-Saharan Africa, where it is projected to
affect >20 million people by 2030 [1, 2]. In Nigeria alone, dia-
betes affects between 0.6% and 11.0% of the population and is
an increasing public health problem [3]. With its signiﬁcant
complication burden, diabetes presents a major burden to pa-
tients, their families, and healthcare systems.
Nigeria also has the second largest number of individuals in-
fected with human immunodeﬁciency virus (HIV) in the Afri-
can continent, with >3 million people living with HIV/AIDS
(PLWHA) and 600 000 receiving antiretroviral therapy (ART)
[4]. PLWHA nowadays have longer survival with expanding ac-
cess to ART, and the prevalence of HIV/diabetes comorbidity is
increasing. Despite its potential public health consequences,
large studies on the relationship between HIV/AIDS and diabe-
tes are still uncommon.
HIV [5–7], ART [8–10], and hepatitis C virus (HCV) [8, 10]
have been implicated as risk factors for diabetes. HIV causes in-
sulin resistance and dyslipidemia [11], and HCV is associated
with intrahepatic elevation of tumor necrosis factor–α levels, in-
sulin resistance, and liver disease [12]. Although initial studies
associated the onset of diabetes in PLWHA to ART containing
protease inhibitors (PIs) [13, 14],which cause hyperglycemia by
preventing the uptake and metabolism of glucose and lipids by
adipocytes and hepatocytes [15], ﬁndings subsequently pointed
toward the nucleoside reverse transcriptase inhibitors (NRTIs)
and nonnucleoside reverse transcriptase inhibitors by virtues of
their mitochondrial toxicity and apoptosis of adipocytes [9, 16].
However, recent studies have suggested that traditional risk fac-
tors for diabetes such as age and body weight are the major pre-
dictors of the development of type 2 diabetes mellitus (T2DM),
as opposed to medications [6].
We have therefore determined the prevalence of T2DM in
ART-naive patients at the time of enrollment into a cohort of
newly diagnosed PLWHA, and describe the proportion of pa-
tients who developed T2DM within 1 year of ART initiation
in a large HIV/AIDS cohort in Jos, Nigeria.
Received 2 March 2016; accepted 26 May 2016; published online 15 June 2016.
aL. E. C. and G. V. G. contributed equally to this work.
Correspondence: S. E. Isa, Department of Medicine, Jos University Teaching Hospital, PMB
2073, Jos, Nigeria (ejijisa@yahoo.com).
Clinical Infectious Diseases® 2016;63(6):830–5
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of
America. This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/
4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
DOI: 10.1093/cid/ciw381
830 • CID 2016:63 (15 September) • HIV/AIDS
METHODS
This was a cross-sectional survey of all newly registered patients
attending the Prevention Initiative of Nigeria (APIN) adult
ART clinic of Jos University Teaching Hospital. The APIN clin-
ic is a regional referral center that provides comprehensive HIV/
AIDS services for Plateau State in north-central Nigeria, with
about 3 million population. Upon registration, all patients un-
dergo an induction that includes lifestyle advice, clinical and
laboratory investigations, and assessment of ART eligibility. Pa-
tients are then followed fortnightly, monthly, quarterly, and
bianually depending on whether they have symptoms or have
initiated ART. Sociodemographic, clinical, and laboratory infor-
mation is entered into standardized forms and uploaded onto a
single electronic database developed in FileMaker Pro (version
10) in computers to ensure data consistency and completeness.
The database is cleaned and curated using routine data manage-
ment training and quality checks. Data errors for the study were
further corrected by checking the original patient case notes and
the electronic databases.
Data on all patients ≥18 years old registered for treatment,
care, and support were retrieved from the database to generate
a retrospective cohort of patients initiating ART from 1 January
2011 to 31 December 2013. Patients without baseline plasma
glucose records and those who had already initiated ART at
the time of enrollment were excluded from the analysis of base-
line diabetes. The precision for estimates was approximately
±1% based on 2632 patients who met the selection criteria
and an assumed prevalence of diabetes of 3% in Jos [17]. This
post hoc precision was calculated using a standard formula [18].
Data retrieved included age, sex, body mass index (BMI),
total cholesterol (mmol/L), CD4+ cell count (per µL), HIV
RNA load (copies/mL), ART regimen, and the presence of
diabetes. ART was categorized as ﬁrst-line or second-line.
The most frequently prescribed ﬁrst-line regimens were
lamivudine + zidovudine + nevirapine (45.9%), and lamivudine
or emtricitabine + tenofovir + efavirenz (31.4%). The most
readily available ﬁrst-line regimen was nevirapine-containing
ART. The second-line ART contained atazanavir/ritonavir
(92%) and lopinavir/ritonavir (8%). Nevirapine-containing
ART was generally avoided in patients with liver disease or
was switched to efavirenz in those who developed hypersensi-
tivity reactions (hepatotoxicity or skin rash). Efavirenz was
also preferred in patients with tuberculosis. However, efavirenz
was avoided in individuals with severe mental health issues or in
women of childbearing age, except if given with contraception.
Second-line regimens were considered if there was suspicion of
transmitted resistance (eg, newly infected contacts of PLWHA
with known ART resistance), a diagnosis of tuberculosis (as ri-
fabutin was not readily available), Kaposi sarcoma, or adverse
effects to the ﬁrst-line regimens. In our clinic, a switch to sec-
ond-line ART due to treatment failure is generally considered
after 12 months of ART and therefore not a reason for use in
this study.
Diabetes was deﬁned as a random plasma glucose level of
≥11.1 mmol/L, fasting plasma glucose of ≥7.0 mmol/L, or
self-reported use of hypoglycemic agents [19]. Plasma glucose
measurements were repeated if classic osmotic symptoms
were not present, to conﬁrm the presence of diabetes. Pregnant
women were not included in the database used for this study as
pregnant women were monitored in a separate service. Hyper-
cholesterolemia was deﬁned according to the US National Cho-
lesterol Education Program [20]. The estimated glomerular
ﬁltration rate (eGFR) was derived by the Cockcroft-Gault for-
mula [21]. A Cobas C311 auto analyzer was used for plasma
chemistry, and HCV antibodies were documented by enzyme-
linked immunosorbent assay.
The main outcomes were the proportion of ART-naive
participants with T2DM at the time of enrollment and the in-
cidence of T2DM among patients without diabetes on enroll-
ment 12 months after initiation of ART.
Ethical approval was obtained from the Liverpool School of
Tropical Medicine and the Jos University Teaching Hospital
Ethics committees. The identity of all patients was anonymized
across the data set by replacing their names with initials and se-
rial numbers.
Statistical analysis was conducted using SPSS software (IBM
SPSS, Chicago, Illinois). Continuous variables were expressed as
mean ± standard deviation, or median (range). Categorical vari-
ables were presented as proportions and compared using χ2
test. Means were compared using unpaired Student t tests. Posi-
tively skewed data were log10 transformed. Bivariate analysis was
conducted and variables with P < .25 were entered into multiple
logistic regression models. Results of the bivariate analyses and lo-
gistic regressions were presented as odds ratios and adjusted odds
ratios (AORs), with 95% conﬁdence intervals (CIs), respectively.
A P value <.05 was considered statistically signiﬁcant.
RESULTS
A total of 2753 patients were recruited in the study period. Of
these, 2632 (96%) had the information required to assess the
presence of diabetes at baseline and 93% (2452/2632) had
new-onset diabetes 1 year after initiation of ART, as shown in
Figure 1. The baseline characteristics of the overall cohort are
shown in Table 1.
Sixty-one of 2632 patients (2.3% [95% CI, 1.8%–2.9%]) had
T2DM on enrollment. Of these, 21 (41%) were unaware of the
diagnosis. Patients with T2DM were older and had signiﬁcantly
lower eGFR than patients without T2DM (Table 2). There was
no difference in sex distribution, BMI, cholesterol levels, CD4+
count, HIV RNA load, or HCV-positive status. Patients >40
years of age were 3.5 times more likely to have T2DM (AOR,
3.5 [95% CI, 1.9–6.5]; P < .001), and patients with T2DM
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were more likely to have reduced eGFR (AOR, 0.99 [95% CI,
.97–.98]; P < .017).
Of the 2452 patients without T2DM on enrollment, 130
(5.3% [95% CI, 4.2%–6.3%]) developed T2DM within 1 year
of initiating ART. If these patients are added to those already
identiﬁed on enrollment, 191 (7.6%) of the participants had
T2DM 1 year after initiating ART.
Patients who developed T2DM after initiation of ART had
higher BMI and were more likely to have HCV antibodies on
enrollment (12.1% and 3.6% of the patients with and without
incident T2DM; P < .001). There were no differences in age,
sex, cholesterol concentrations, CD4+ count, HIV RNA load,
eGFR, or the use of ﬁrst- or second-line ART among patients
with and without incident T2DM (Table 3).
Variables included in the logistic regression model were BMI,
cholesterol ≥5.2 mmol/L, CD4+ cells/mL, viral load, eGFR, and
the presence of HCV antibodies. Of these, only BMI ≥25 kg/m2
(AOR, 7.5 [95% CI, 2.9–23.7]; P < .001) was independently as-
sociated with incident T2DM (Table 3).
DISCUSSION
Our study of a large cohort of HIV-infected Nigerians enrolled
for ART showed a baseline diabetes prevalence of 2.3%. This
was associated positively with age and inversely with renal func-
tion but surprisingly not with BMI. After 12 months of ART, an
additional 5.3% had developed T2DM. In this group, diabetes
was not associated with age, but was positively associated with
BMI and the presence of HCV antibodies on enrollment. Of
these, only BMI >25 kg/m2 was independently associated with
newly developed T2DM in multivariate analysis.
The baseline T2DM prevalence is similar to other reports in
both ART-naive and -experienced patients [6, 22]. However, in
Italy, investigators reported a higher prevalence of 4.1% among
ART-experienced patients [5], and in China 10.5% of ART-
naive patients had T2DM [7]. Patients in Italy were older (46
vs 37 years) and had signiﬁcantly higher CD4+ counts than pa-
tients in our study (538 vs 206 cells/µL), while the prevalence of
diabetes in a Chinese population [23] was higher than in Nigeria,
suggesting that prevalence of T2DM may vary with the overall
T2DM prevalence in the general population, HIV disease pro-
gression, and the disease stage when patients access ART.
Similarly, our 5.3% incidence of T2DM among patients on
ART is similar to the 6.0% reported in the United States [23],
but lower than a 7.2% 3-year cumulative incidence among
Table 1. Overall Characteristics of the Individuals Enrolled in the Cohort
(N = 2632)
Variable No. (%)
Age, y
Mean (SD) 37.4 ± 9.7
Median (range) 36 (19–79)
Proportion >40 years old 958 (36.4%)
Male/female (% male) 924/1708 (35.1%)
Mean (SD) body mass index, kg/m2 22.9 (4.8)
Total cholesterol, mean (SD), mmol/L 4.1 (1.3)
Median (range) CD4+ count, cells/µL 190 (2–1837)
Geometric mean (SD) viral load, copies/mLa 4.3 (0.9)
Mean (SD) eGFR, mL/minb 79.6 (24.8)
HCV antibody present, no./No. (%)c 69/1645 (41.9%)
ART regimend
3TC + ZDV +NVP 1125 (45.9%)
3TC or FTC + TDF + EFV 769 (31.4%)
3TC + NVP + TDF 281 (11.6%)
3TC + ZDV + EFV 59 (2.1%)
ATV/RTV-based PI 64 (2.5%)
LPV/RTV-based PI 4 (0.3%)
Othere 150 (6.2%)
Data are presented as No. (%) unless otherwise indicated. Only patients followed up for
incident diabetes were exposed.
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV, atazanavir;
EFV, efavirenz; eGFR, estimated glomerular filtration rate; FTC, emtricitabine; HCV,
hepatitis C virus; LPV, lopinavir; NVP, nevirapine; PI, protease inhibitor; RTV, ritonavir; SD,
standard deviation; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
a n = 2140.
b n = 2157.
c n = 1714.
d n = 2452.
e Other regimens: ZDV + FTC + TDF, 3TC + NVP + ABC, 3TC + ABC + EFV, 3TC + ZDV +
TDF.
Figure 1. Flowchart of patient selection for the study. Abbreviation: ART, antire-
troviral therapy.
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recipients of early-generation PIs [24]. T2DM development is a
progressive condition that may require several years to become
established among PLWHA, and longer-term follow-up may be
needed to establish total cumulative risk.
The association of age with baseline diabetes in HIV cohorts
was reported by Mehta et al [25], who calculated an AOR of 3.5
among patients ≥50 years of age, and by Brar et al [6], who es-
timated an AOR of 3.0 for every 10-year age increment. The lack
of association between age and incident diabetes after ART ini-
tiation was also reported by Yoon et al [26]. However, others
have reported that there are associations between age and inci-
dent diabetes in French and multinational cohorts [8, 9]. These
varying ﬁndings may be due to differences in study design, and
in the duration and type of ART used across studies.
In our study, patients with T2DM at enrollment were more
likely to have a lower eGFR, whereas there was no association
with incident diabetes. It is possible that those with diabetes
at baseline had had the disease for sufﬁciently long duration
to affect kidney function, unlike incident cases who had devel-
oped diabetes within <1 year. Although older age, lower CD4+,
and higher BMI may reduce eGFR in HIV/AIDS, data on the
relationship between eGFR and diabetes in HIV-infected people
are scarce. We did not have data on the duration of diabetes be-
fore enrollment, but Medapalli et al [27] demonstrated a greater
probability for progression to chronic kidney disease in patients
with HIV infection and diabetes, compared with HIV infection
alone, in a large cohort followed over a 5-year period.
The association between HCV and T2DM has been reported
previously [6, 25].Nevertheless, not all studies have reported this
association, as the large Swiss HIV Cohort Study reported that
HCV did not increase the risk of diabetes [10]. The presence
of HCV antibodies is not synonymous with active infection,
and further studies are needed to evaluate whether recent or
current infection increases the risk of diabetes.
Unexpectedly, BMI was not associated with baseline diabetes,
in contrast with other series [5, 6], but it was associated with
newly developed diabetes on ART, as previously reported [8,
9]. The weight loss that may occur with uncontrolled diabetes
may be responsible for this lack of association, as 41% of pa-
tients were unaware of their T2DM diagnosis. Also, other com-
mon HIV-related illnesses causing weight loss (such as diarrhea
and tuberculosis) might have masked the association at
Table 2. Characteristics of Patients With and Without Diabetes at Baseline in a Cohort of People Living With Human Immunodeficiency Virus in Jos,
Nigeria (N = 2452)
Characteristics
With Diabetes
(n = 61 [2.3%])
Without Diabetes
(n = 2571 [97.7%]) OR (95% CI) P Value
Age >40 y 43/61 (70.5%) 915/2571 (35.6%) 4.32 (2.48–7.54) .0001
Male:female (% male) 25:36 (41%) 899:1656 (35%) 1.29 (.77–2.16) .330
BMI ≥25 kg/m2 22 (36.1%) 830 (32.3%) 1.13 (.79–1.65) .490
Mean (SD) cholesterol, mmol/L 4.1 (1.4) 4.1 (1.3) 1.07 (.94–1.23) .980
Median (range) CD4+ count, cells/µL 180 (10–867) 190 (2–1837) 1.00 (1.00–1.00) .938
Log mean (SD) viral load, copies/mL 4.3 (0.9) 4.3 (0.9) 1.00 (1.00–1.00) .340
Mean (SD) eGFRa, mL/min 67.5 (22.3) 79.9 (24.8) 0.98 (.97–.99) .005
Positive HCV antibody 1/40 (2.5%) 68/1674 (4.1%) 0.61 (.08–4.47) .619
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; OR, odds ratio; SD, standard deviation.
a Variable with P < .25 in bivariate analysis.
Table 3. Bivariate and Multivariate Analysis of Risk Factors of New-Onset Diabetes in a Cohort of People Living With Human Immunodeficiency Virus on
Antiretroviral Therapy in Jos, Nigeria (N = 2452)
Characteristic
New-Onset Diabetes
(n = 130 [5.3%])
No Diabetes
(n = 2322 [94.7%]) OR (95% CI) AOR (95% CI) P Value
Age >40 y 51 (39.2%) 822 (35.4%) 1.13 (.79–1.61) 1.02 (.99–1.05) .14
Mean (SD) cholesterola, mmol/L 4.2 (1.2) 4.1 (1.3) 1.07 (.94–1.23) 0.88 (.71–1.10) .23
Median (range) CD4+ counta, cells/µL 206 (13–968) 188 (2–1837) 0.98 (.90–1.10) 1.00 (1.00–1.02) .90
Log (SD) mean viral loada, copies/mL 4.5 (0.89) 4.3 (0.92) 0.91 (.89–1.09) 1.21 (.90–1.64) .21
Mean (SD) eGFRa, mL/min 78.9 (25.3) 80.0 (24.8) 1.01 (.99–1.03) 0.99 (.99–1.01) .85
Positive HCV antibodya 12/99 (12.1%) 56/1575 (3.6%) 1.15 (1.03–1.28) 2.46 (.58–10.54) .22
First-line ART 123/130 (94.6%) 2245/2306 (97.3%) 1.16 (.97–1.39) NA . . .
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; eGFR, estimated glomerular filtration rate, HCV, hepatitis C virus; OR, odds ratio; NA, not applicable;
SD, standard deviation.
a Variables with P < .25 in bivariate analysis which were also baseline characteristics adjusted for associations with new diabetes. Hosmer and Lemeshow test: χ2 = 9.242; P = .32.
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baseline, and these illnesses were likely to be common in our
cohort due to the low CD4 counts of patients on enrollment.
Markers of HIV progression (CD4+ and viral load) did not
differ between patients with and without T2DM and incident
diabetes, which is in agreement with a previous ﬁnding in the
United States [6]. The association of CD4+ and viral load with
diabetes can be complex, and were not identiﬁed in the compar-
ison of a large cohort of HIV-infected and HIV-uninfected vet-
erans [28]. However, Shen et al had reported a signiﬁcant
increase in diabetes risk for every 150-CD4+ cell/µL reduction
among ART-naive patients [7].
We did not ﬁnd associations between the type of ART regi-
men and diabetes, as reported by Ledergerber et al [10]. De Wit
et al reported that although PIs were not associated with diabe-
tes, there was an association with NRTIs [9], with stavudine fol-
lowed by zidovudine, and didanosine conferring the greatest
risk. In our study, the overall number of individuals on sec-
ond-line ART was small and the majority were on atazanavir-
based PI, which does not have a signiﬁcant effect on glucose
metabolism. In addition, ART adherence and the use of medi-
cations with adverse glycemic effects were not assessed, and
none of the patients received stavudine or didanosine.
Our study has strengths, but also some important limitations.
It is probably the largest study providing concurrent data on
both baseline and new diabetes on ART in HIV/AIDS patients
residing in sub-Saharan Africa. However, our cohort had a rel-
atively short follow-up period of only 1 year, and a longer peri-
od of observation would likely reveal additional patients
developing diabetes, and possibly stronger risk associations.
Furthermore, information such as waist/hip circumference of
patients was not routinely measured in the clinic, and metabolic
markers were coded into dichotomous variables (eg, diabetes
yes/no), precluding further stratiﬁcation for analysis of data.
Also, the study lacks a control cohort of non-HIV-infected sub-
jects and data of PLWHA who did not initiate ART. Last, the
absence of data on prediabetes could represent a missed oppor-
tunity to estimate and plan diabetes prevention initiatives.
In conclusion, diabetes is common among HIV/AIDS pa-
tients on established ART. Traditional risk factors are impor-
tant, and a higher BMI appears to confer the strongest risk.
Body weight is modiﬁable, and supporting patients to achieve
healthy dietary and lifestyle behavior is important, as PLWHA
may overcompensate in weight gain to avoid the stigma associ-
ated with weight loss. The relationship between diabetes and
ART needs further long-term exploration. Patients with HIV
initiating ART need to be aware of the risk of developing diabe-
tes, and services should provide integrated services for HIV/
AIDS and noncommunicable diseases such as diabetes.
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